IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
|
Exhibit Number
|
Description
|
|
|
10.1
|
Confidential Settlement Agreement, by and between the
Company and TheraVectys SA, a French socit anonyme, dated October 17, 2016. |
|
|
10.2
|
License Agreement, by and between the Company and
TheraVectys SA, a French socit anonyme, dated October 17, 2016. |
|
|
Confidential portions of this exhibit have been redacted
and filed separately with the Securities and Exchange Commission to a confidential treatment request in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended. |
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Exhibit Number
|
Description
|
|
|
10.1
|
Confidential Settlement Agreement, by and between the
Company and TheraVectys SA, a French socit anonyme, dated October 17, 2016. |
|
|
10.2
|
License Agreement, by and between the Company and
TheraVectys SA, a French socit anonyme, dated October 17, 2016. |
|
|
Confidential portions of this exhibit have been redacted
and filed separately with the Securities and Exchange Commission |
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA). IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Recent Trading Information
IMMUNE DESIGN CORP. (NASDAQ:IMDZ) closed its last trading session 00.00 at 5.25 with 31,433 shares trading hands.
